

└ **NewYork-Presbyterian**  
└ **Regional Hospital Network**

└ **NewYork-Presbyterian**  
└ **Queens**



**NewYork-Presbyterian Regional Hospital Network  
NewYork-Presbyterian/Queens  
Rogosin Institute  
Symposium**

**“The Future of Nephrology –  
The Next Two Decades and Beyond”**

**Thursday, January 24, 2019**  
8:00 a.m. - 12:30 p.m.

The Rockefeller University  
1230 York Avenue  
New York, NY 10065

## Accreditation

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Medical Society of the State of New York (NYP QUEENS CME) and The Rogosin Institute. NYP QUEENS CME is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

NewYork-Presbyterian/Queens designates this Live Activity for a maximum of **3.0 AMA PRA Category 1 Credits™**. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

## Disclosure

The Medical Society of The State of New York relies upon planners and faculty participants in its CME activities to provide educational information that is objective and free of bias. In this spirit and in accordance with the guidelines of MSSNY and the ACCME, all speakers and planners for CME activities must disclose any relevant financial relationships with commercial interests whose products, devices or services may be discussed in the content of a CME activity, that might be perceived as a real or apparent conflict of interest. Any discussion of investigational or unlabeled uses of a product will be identified.

**“The Future of Nephrology: The Next Two Decades and Beyond”**  
**Thursday, January 24, 2019**

| <b>8:00 – 8:45 a.m. REGISTRATION &amp; CONTINENTAL BREAKFAST</b> |   |  |
|--|---|--|
| <b>8:45 – 8:50 a.m.</b>  | <b>Welcome &amp; Introduction</b>   | <b>Amir Jaffer, MD</b> , Chief Medical Officer<br>New York-Presbyterian/Queens   |
| <b>8:50 – 8:55 a.m.</b>  | <b>Overview/Goals of the Symposium</b>  | <b>Barry H. Smith, MD, PhD</b><br>President & CEO<br>The Rogosin Institute   |
| <b>8:55 – 9:20 a.m.</b>  | <b>Disruptions in Healthcare</b>  | <b>Andrew Waldeck</b><br>Senior Partner<br>Innosight   |
| <b>9:20 – 9:35 a.m.</b>  | <b>New Structural and Functional Models of Kidney Care and Reimbursement</b>            | <b>Bruce Culleton, MD</b><br>Vice President and Chief Medical Officer<br>CVS Health  |
| <b>9:35 – 9:55 a.m.</b>  | <b>The Future for Nephrologists and Nephrology</b>                                      | <b>Tod Ibrahim</b><br>Executive Vice President, American Society of Nephrology<br><b>Rachel Meyer</b><br>Director, Policy and Government Affairs,<br>American Society of Nephrology  |
| <b>9:55 – 10:10 a.m.</b>   | <b>The Role of Nursing in Nephrology’s Future</b>                                       | <b>Mary Schira, PhD, RN, ACNP-BC</b><br>Associate Professor of Nursing, University of Texas,<br>Arlington  |
| <b>10:10 – 10:30 a.m. BREAK</b>                                  |   |  |
| <b>10:30 – 10:40 a.m.</b>  | <b>Artificial Intelligence in the Prevention and Better Treatment of Kidney Disease</b> | <b>Ollie Fielding</b><br>Head of Product, pulseData  |
| <b>10:40 – 10:55 a.m.</b>  | <b>New Treatments – Stem Cells in the Repair and Replacement of Injured Kidneys</b>     | <b>Leif Oxburgh, DVM, PhD</b><br>Faculty Scientist, Maine Medical Center Research Institute, Professor of Medicine, Sackler School of Graduate Biomedical Science, Tufts University<br>Kidney Patient Advisory Council Chair |
| <b>10:55-11:05 a.m.</b>  | <b>Doing More with Less</b>   | <b>Tom Catena, MD</b><br>Sole Medical Doctor, Mother of Mercy Hospital<br>Nuba Mountains, Sudan  |
| <b>11:05-11:15 a.m.</b>  | <b>Behavioral Health: Nephrology’s Next Frontier</b>                                    | <b>Daniel Cukor, PhD</b><br>Director, Behavioral Health, The Rogosin Institute   |
| <b>11:15-11:25 a.m.</b>  | <b>The Future of Nephrology from the Patient’s Perspective</b>                          | <b>Richard Knight</b><br>President<br>American Association of Kidney Patients  |
| <b>11:25 – 12:00 p.m.</b>  | <b>Panel: Speakers and Audience Q&amp;A</b>   | <b>MODERATOR:</b> Barry Smith, MD, PhD   |
| <b>12:00 – 12:10 p.m. CONCLUDING STATEMENT AND EVALUATIONS</b>   |   |  |

# SPEAKERS

## ***Andrew Waldeck* - KEYNOTE SPEAKER**

**Andrew Waldeck** is a Senior Partner at Innosight, where he leads the healthcare practice. Over the past ten years at Innosight, Andy has advised senior leaders at companies such as Aetna, Baxter, Covidien (now part of Medtronic), and Walgreens. He has extensive experience across the healthcare industry including, payers, providers, medical devices, pharmaceuticals, pharmacy and health information technology.

At Innosight, Andy's work focuses on helping clients to develop long-term growth strategies, manage enterprise transformation, build enduring growth and innovation capabilities and design new disruptive growth businesses. In addition to his work leading the healthcare practice, Andy also has worked with other Fortune 500 companies across the media, financial services and consumer industries.

Andy is a frequent speaker and author on topics of healthcare transformation, disruption and long-term growth. He is the co-author most recently of *How Disruption can Finally Revolutionize Health Care*, *Knowing When to Reinvent* and *The New M&A Playbook*.

Andy's experience with growth and innovation stems from his past work with early-stage growth companies as both an investment banker and venture capitalist. Prior to joining Innosight, Andy was a Managing Director at the investment bank C.E. Unterberg, Towbin, where he completed 50 financial and strategic transactions totaling over \$5B in transaction value. Most recently, Andy was a Vice President at GrandBanks Capital, an early stage IT-focused venture capital fund.

Andy received a B.A. in Business Economics from Brown University and a M.B.A with Distinction from the Tuck School of Business at Dartmouth, where he was a Tuck Scholar. He lives in Concord, MA with his wife and three children.

## **PUBLICATION HIGHLIGHTS**

"Health for Hire: Unleashing Patient Potential to Reduce Chronic Disease Costs," *Harvard Business Review*, 2017.

"How Disruption Can Finally Revolutionize Health Care," *Harvard Business Review*, 2017.

## ***Bruce Culleton***

**Dr. Bruce Culleton** serves as Vice President and Chief Medical Office for the Kidney Care business at CVS Health. He is responsible for clinical research, medical and scientific activities, and guidance to all strategic initiatives for the developing business. Prior to his current role, Bruce was Vice President of Global Clinical Development at Becton Dickinson (BD). In that role he had responsibility for all clinical studies conducted across the company as well as medical affairs activities in support of the BD's medical-surgical business. Prior to BD, Bruce led the Renal Global Medical Affairs team at Baxter Healthcare. Before joining industry in 2007, Bruce was an academic nephrologist at the University of Calgary in Alberta, Canada. Bruce received his MD (1991) from Memorial University of Newfoundland, Canada; Fellowship Diplomas in Internal Medicine (1995) and Nephrology (1997) from the Royal College of Canada and Clinical Epidemiology from the Framingham Heart Study, MA (1999); and an MBA from Kellogg School of Business in Evanston, IL (2010).

## ***Tod Ibrahim***

**Tod Ibrahim** is Executive Director of the American Society of Nephrology, which represents nearly 15,000 kidney care professionals in more than 110 countries. Prior to this position, he was founding Executive Vice President of the Alliance for Academic Internal Medicine, Director of Public Policy for the Association of Professors of Medicine, Director of Communications for Robert Betz Associates, and Staff Assistant for US Representative Thomas C. Sawyer (D-OH). A two-time recipient of George Washington University's Jenny McKean Moore scholarship for poets, Tod has a master's degree in liberal arts from Johns Hopkins University and a bachelor's degree in English from the University of Maryland at College Park.

He is the author or coauthor of many articles, including "The Kidney Research Predicament"; "Recruiting the Next Generation of Nephrologists"; "The Future Nephrology Workforce: Will There Be One?"; "The Impact of Increasing Medical School Class Size on Clinical Clerkships: A National Survey of Internal Medicine Clerkship Directors"; "Tenures for Department Chairs: How Short Is Too Short?"; "Globalization: A New Dimension for Academic Internal Medicine"; "Centers, Institutes, and the Future of Clinical Departments"; and "Developing a Strategy for Providing Federal GME Support." Recently, Tod coauthored a chapter for the *Guidebook for Clerkship Directors* entitled "Understanding, Navigating, and Leveraging US Medicine".

## ***Rachel Meyer***

**Rachel Meyer** is the Director of Policy and Government Affairs at the American Society of Nephrology and oversees the society's federal legislative and regulatory advocacy portfolio. Meyer administers ASN's patient care and research-related advocacy efforts, working with Congress as well as federal agencies including the Centers for Medicare and Medicaid Services, the Food and Drug Administration, and the National Institutes of Health to influence policies that affect nephrology health professionals and the patients they serve.

Prior to joining ASN, she conducted healthcare research at the Advisory Board Company in Washington, DC, and worked for Senator Ken Salazar (D-CO) in his district office. Rachel has a degree in Global Health and Development from the Colorado College.

She has co-authored numerous articles, including "Fostering Innovation, Advancing Patient Safety: The Kidney Health Initiative"; "Comparing Mandated Health Care Reforms: The Affordable Care Act, Accountable Care Organizations, and the Medicare ESRD Program"; and "Considering an Integrated Nephrology Care Delivery Model: Six Principles for Quality."

## ***Mary Schira***

**Mary Schira**, PhD, RN, ACNP-BC is Associate Professor at the University of Texas at Arlington College of Nursing and Health Innovation where she teaches in the Nurse Practitioner and Doctor of Nursing Practice Programs. Mary has been a nurse in Nephrology for over 40 years and an NP for over 15 years. Most of Dr. Schira's career has been in nursing education – at the undergraduate and graduate levels.

Mary is a frequent presenter and has made numerous presentations related to professional development, kidney disease, evidence based guidelines and outcomes, and professional practice topics. Mary is active in the American Nephrology Nurses Association where she has held numerous volunteer positions, serving on Committees, the Journal Editorial Board and the Advanced Practice Special Interest Group. She is currently Chair of the Conferences Committee.

## ***Ollie Fielding***

**Ollie Fielding** is the Head of Product at pulseData, who work to improve patient outcomes by building data models that identify patients at high-risk of specific, acute events. Ollie is passionate about solving healthcare's greatest challenges, having started out at 16 working in his local hospital laboratory testing blood samples. Following a quick diversion to study at Cambridge University, he joined Rotamap, where he helped design and shape medical scheduling systems from the ground up. Ollie devised a series of national KPI metrics and benchmarking tools for hospital departments in the UK and has acted as an advisor to government medical bodies on productivity, service improvement and workforce intelligence.

## ***Leif Oxburgh***

**Leif Oxburgh**, DVM, PhD, is faculty scientist, Maine Medical Center Research Institute and Professor of Medicine, Sackler School of Graduate Biomedical Science at Tufts University. Dr. Oxburgh's research is centered around the study of regenerative medicine for kidney disease. His lab focuses on understanding the basic molecular mechanisms that regulate the balance between renewal and differentiation in the nephron progenitor cell, which gives rise to the filtering unit of the kidney. In parallel with pursuing these studies in basic biology, he is developing new strategies to recreate the progenitor cell environment of the fetal kidney in the laboratory with the goal of generating new kidney tissue from stem cells. One important application of this technology is the creation of accurate models of human disease that reflect the complexity of the organ, leading to more effective therapies for the treatment of kidney diseases and certain cancers. A distant goal of this research is generating new kidney tissue for patients to relieve the transplant organ shortage.

Dr. Oxburgh received his DVM and then his PhD (in virology) from the Swedish University of Agricultural Sciences, in 1992 and 1998, respectively. He went on to perform postdoctoral research in molecular and cellular biology at Harvard University from 1999-2004. He has held his current position as Principal Investigator at the Maine Medical Center Research Institute since 2004.

## ***Tom Catena***

**Tom Catena**, MD is a surgeon, veteran, catholic missionary, globally-recognized humanitarian, and inaugural Chair of the Aurora Humanitarian Initiative.

In his role as Aurora Chair, Dr. Catena engages with politicians, humanitarian organizations, practitioners, and everyday people around the world to spread the message of Gratitude in Action. Founder of the Mother Mercy Hospital in Sudan's war-ravaged Nuba mountains, Dr. Catena has dedicated the last decade of his life to providing medical care as the only surgeon permanently based in a region the size of Austria. Despite an effective embargo on humanitarian supplies, the withdrawal of other NGOs, and the constant threat of air raids on the hospital, Dr. Catena provides treatment for more than 750,000 people suffering ailments from malnourishment and typhoid, to cancer and war wounds.

(Tom Catena- continued)

A graduate of Duke University's School of Medicine, Dr. Catena began his medical career in the United States Navy, serving four years as a flight surgeon. Following his residency, Dr. Catena spent six years as a volunteer at St. Mary's Hospital in Nairobi, Kenya, before moving to Sudan to cofound the hospital he still leads.

In 2017, Dr. Catena was awarded the \$1.1 million Aurora Prize for Awakening Humanity, which honors unsung heroes working to preserve human life at great personal risk.

He is the recipient of Honorary Doctorates from Brown University (2016) and Yerevan State Medical University (2017) and was named one of the 100 most influential people by Time magazine in 2015.

Tom Catena was appointed Aurora's inaugural Chair in December 2018, a position he maintains in parallel with his ongoing responsibilities as Medical Director of the Mother Mercy Hospital in Sudan.

### ***Daniel Cukor***

**Dr. Daniel Cukor** is currently the Director of Behavioral Health at The Rogosin Institute. He received his Ph.D. in Clinical Health Psychology from Ferkauf Graduate School/Albert Einstein College of Medicine (2002). He did a post-doctoral fellowship in cognitive behavioral therapy treatment and research at Downstate Medical Center.

The bulk of his research has focused on psychosocial issues in patients with end stage renal disease. He has received grant support for his research, has authored many scientific articles and is a sought after speaker in the field of psychonephrology. He is currently editing a comprehensive textbook entitled "Psychosocial Aspects of Chronic Kidney Disease". His current research interests are focused on depression, sleep difficulty, pain and caregiver burden in patients with end stage renal disease. He is also an active clinician, consulting and treating patients at The Rogosin Institute.

### ***Richard Knight***

**Richard Knight** is a former hemodialysis patient who received a kidney transplant approximately nine years ago. Mr. Knight is a certified public accountant and small business owner who is heavily involved in business and education issues through various professional networks in Maryland and Washington, D.C. He is a graduate of Hampton University and the University of Virginia Darden School of Business. Mr. Knight has a substantial background in public policy and Congressional operations based on both his advocacy work as a kidney transplant patient as well as his professional experience on Capitol Hill where he served in various roles including communications, policy and Chief of Staff. Mr. Knight was also the representative for his Member of Congress to the Congressional Black Caucus of the U.S. House of Representatives. Richard is currently a Business Strategist, providing patient engagement consulting for healthcare organizations and serving as a patient advocate for businesses seeking patient input and guidance in pursuing better and more affordable care. He is also an adjunct professor at Bowie State University, where he teaches graduate and undergraduate courses in the College of Business.

(Richard Knight - continued)

He is currently Vice President and Chair of the American Association of Kidney Patients (AAKP) Public Policy Committee, a member of the National Kidney Disease Educational Program Health Information Technology Working Group, and a member of the Board of Directors of the Mid-Atlantic Renal Coalition (MARC). Mr. Knight is also a member of the Technical Expert Panel (TEP) focusing on Hospital Readmissions for Arbor Research Collaborative for Health and the University of Michigan Kidney Epidemiology and Cost Center, a founding member of the End Stage Renal Disease (ESRD) Health Information Technology (HIT) Project, a member of the steering committee for the Coalition for Supportive Care of Kidney Patients and also participated in the Fistula First Breakthrough Initiative.



## **NewYork-Presbyterian** **Regional Hospital Network**

NewYork-Presbyterian, based in New York City, is a world-class academic healthcare delivery network dedicated to providing the highest quality and most advanced care to patients and families in the Greater New York area and across the country. In collaboration with two world-renowned medical school partners, Weill Cornell Medicine and Columbia University College of Physicians & Surgeons, NewYork-Presbyterian delivers patient-centered care to one of the most diverse populations in the world, conducts groundbreaking medical research and develops leading clinical innovations.

NewYork-Presbyterian comprises four major divisions: NewYork-Presbyterian Hospital, a world-class academic medical center ranked the #1 hospital in the New York metropolitan area by U.S. News and World Report, and consistently named to the magazine's Honor Roll of best hospitals in the nation; NewYork-Presbyterian Regional Hospital Network, comprised of leading regional hospitals in the New York metro region; NewYork-Presbyterian Physician Services, which brings medical experts to patients in convenient locations in their communities; and NewYork-Presbyterian Community and Population Health, comprised of the institution's ambulatory care network sites and operations, community programs and initiatives and healthcare quality programs including NewYork Quality Care, the Accountable Care Organization jointly established by NewYork-Presbyterian, Weill Cornell and Columbia.

NewYork-Presbyterian is committed to excellence in patient care, research, education and community health. For more information, visit [www.nyp.org](http://www.nyp.org).

## **NewYork-Presbyterian** **Queens**

NewYork-Presbyterian/Queens is a member of the NewYork-Presbyterian Regional Hospital Network. NewYork-Presbyterian/Queens is committed to being a premier healthcare institution serving our greater community by providing excellence in clinical care and patient safety, education, clinical research and service.

For more information, visit [www.nyp.org/queens](http://www.nyp.org/queens)



The Rogosin Institute, a member of the NewYork-Presbyterian Regional Hospital Network, provides the best possible health care and quality of life for people with kidney disease, as well as those with diabetes, lipid and cardiovascular disorders, and cancer.

The Rogosin Institute's primary mission is to:

- Provide optimal clinical care and quality of life for patients with chronic diseases
- Foster innovative basic and clinical research to find new and better treatments
- Promote humanitarian and quality health outreach programs to individuals, families, and communities, along with public policy initiatives that advance health and prevent disease

The Rogosin Institute is committed to produce a unique applicable model for optimal, cost-effective health care and health promotion.

For additional information, visit: [www.rogosin.org](http://www.rogosin.org)